Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | |
|---|---|---|---|---|---|
| 1 | 64 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 3 years for example carcinoma in situ of the | 9 | oral cavity | 21 |
| 2 | 33 | uteri or | 8 | 11 | |
| 3 | 34 | history of malignancy other than non melanoma skin cancer or carcinoma in situ e . g . cervix bladder | 4 | from which the patient has been disease free for > = 3 years | 7 |
| 4 | 3 | 3 | unless disease free for at least 3 years | 5 | |
| 5 | 5 | history of second malignancy other than non melanoma skin cancer or in situ carcinoma of the cervix or the | 2 | cancer or cervix cancer unless the tumor was successfmcLly treated with curative intent at least 2 years before trial entry | 3 |
| 6 | 15 | other cancer except that for which the transplant was done < 2 years before study entry except non melanoma skin cancer or carcinoma in situ of the uterine cervix or | 2 | or cervix | 3 |
| 7 | 25 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 3 years with the exception of those with a negligible risk of metastases or death such as carcinoma in situ of the | 2 | unless the tumor was successfmcLly treated at least 2 years before trial entry and with no evidence of relapse or active cancer | 2 |
| 8 | 27 | prior invasive non | 2 | unless in complete remission with no therapy for a minimum of 3 years . | 2 |
| 9 | 40 | uterus or | 2 | cancer in situ or r n prior malignancy completely excised or removed and patient has been continuously disease free for > = 5 years or r n prior malignancy cured by non surgical modalities and patient has been continuously disease free for > = 5 years | 2 |
| 10 | 49 | history of malignancy other than nonmelanoma skin cancer or carcinoma in situ e . g . cervix bladder | 2 | or follicmcLar lymphoma unless disease free for at least 3 years | 2 |
| 11 | 71 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 3 years non invasive conditions such as carcinoma in situ of the | 2 | cancer is allowed | 2 |
| 12 | 72 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 1095 days 3 years for example carcinoma in situ of the | 2 | oral cavity or cervix are all permissible | 2 |
| 13 | 74 | prior invasive malignancy except for non melanomatous skin cancer unless disease free for > = 3 years for example carcinoma in situ of the | 2 | and appropriately treated in situ / early stage cervical / endometrial cancer | 2 |
| 14 | 77 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 1095 days 3 years noninvasive cancers for example carcinoma in situ of the | 2 | . | 1 |
| 15 | 1 | no history of other cancer except non melanoma skin cancer or in situ | 1 | of cervix are allowed . | 1 |
| 16 | 2 | exclusion procurement history of other cancer except non melanoma skin cancer or in situ | 1 | oral cavity or cervix . | 1 |
| 17 | 4 | pior history of treated malignancy in the past 2 years . subjects with non melanoma skin cancer localized prostate cancer and carcinoma in situ of the | 1 | cancer | 1 |
| 18 | 6 | procurement exclusion critera r n active infection requiring antibiotics r n no history of other cancer except non melanoma skin cancer or in situ | 1 | cancer or a history of any other cancer except nonmelanoma skin cancer or carcinoma in situ of the cervix unless in complete remission with no therapy for a minimum of 3 years | 1 |
| 19 | 7 | prior additional malignancy within 2 years except for non melanoma skin cancer carcinoma in situ of the | 1 | cancer participants who are stable on antiestrogen therapy may have that treatment continued | 1 |
| 20 | 8 | second primary malignancy within the past 2 years except non melanoma skin cancer in situ carcinoma of the cervix | 1 | carcinoma after complete surgical resection or superficial transitional cell bladder carcinoma | 1 |
| 21 | 9 | have a history of any other cancer except non melanoma skin cancer or carcinoma in situ of the cervix or | 1 | that does not require further treatment . | 1 |
| 22 | 10 | have a history of any other cancer except nonmelanoma skin cancer or carcinoma in situ of the cervix or | 1 | carcinoma phase ii except for non melanoma skin cancer or curatively treated carcinoma in situ of the cervix diagnosed during the past five years | 1 |
| 23 | 11 | other active malignancy = < 3 years prior to registration exceptions non melanoma skin cancer prostatic intraepithelial neoplasia without evidence of prostate cancer lobmcLar carcinoma in situ in one | 1 | or completely resected non melanoma skin cancer | 1 |
| 24 | 13 | have inflammatory | 1 | cancer or prostate cancer second malignancies are eligible after discussion with the study principal investigator pi | 1 |
| 25 | 14 | previous malignancy within 2 years prior to the first dose of arq 087 except curatively treated non melanoma skin cancer carcinoma in situ of the | 1 | or cervix or pre cancerous lesions of the colon | 1 |
| 26 | 16 | have a history of any other cancer except non melanoma skin cancer or carcinoma in situ of the cervix unless in complete remission and off all therapy for that disease for a minimum of 3 years . at the discretion of the investigator hormone refractory prostate cancer participants who are stable on gnrh agonist therapy and | 1 | cancer unless disease free for a minimum of 3 years | 1 |
| 27 | 17 | previous malignancy within 2 years of the first dose of arq 087 except curatively treated or low grade malignancies such as non melanoma skin cancer carcinoma in situ of the | 1 | malignancy except non melanomatous skin cancer carcinoma in situ of the cervix unless disease free for a minimum of 3 yrs prior to study entry | 1 |
| 28 | 18 | in situ | 1 | malignancy except non melanomatous skin cancer unless disease free for a minimum of 1 year prior to registration | 1 |
| 29 | 19 | patients with another malignancy in the past 3 years except curatively treated non melanoma skin cancer or carcinoma in situ either cervix or | 1 | malignancy unless disease free for a minimum of 1 year prior to registration | 1 |
| 30 | 20 | malignancy other than | 1 | adenocarcinoma adequately treated non melanomatous skin cancer or other non invasive carcinoma or in situ neoplasm . a participant with previous history of malignancy is eligible | 1 |
| 31 | 22 | patients must not have any history of other cancer within 5 years from registration with the exception of in situ carcinoma of the cervix in situ carcinoma of the | 1 | from which the patient has been disease free for at least 3 years second primary breast cancers are allowed regardless of the number of years since they were first diagnosed | 1 |
| 32 | 23 | history of another malignancy exception subjects who have been disease free for 3 years or subjects with a history of completely resected non melanoma skin cancer and / or subjects with indolent early stage | 1 | from which the patient has been disease free for = < 3 years | 1 |
| 33 | 24 | patients with a past or current second malignancy are not eligible aside from the following exceptions r n patients who have been free of malignancy for at least 5 years r n patients who have a history of completely resected basal or squamous cell skin cancer successfmcLly treated in situ carcinoma of the | 1 | unless the patient has been disease free for > = 3 years | 1 |
| 34 | 26 | prior invasive malignancy except non melanomatous skin cancer curatively resected thyroid papillary carcinoma and invasive and non invasive cancers related to the | 1 | from which the patient has been disease free for 3 years | 1 |
| 35 | 28 | prior history of invasive non | 1 | prostate . if there is a history of prior malignancy patient must not be receiving other specific treatment other than hormonal therapy for the cancer . | 1 |
| 36 | 31 | participant has a concurrent active malignancy other than | 1 | carcinoma in situ dcis or carcinoma in situ of the cervix r n note if there is a history or prior malignancy they must not be receiving other specific treatment for their cancer | 1 |
| 37 | 32 | or | 1 | or prostate cancer are permitted if they meet other eligibility criteria patients with non melanotic skin cancer may enroll | 1 |
| 38 | 38 | history of malignancy other than nonmelanoma skin cancer or carcinoma in situ eg cervix bladder | 1 | prostate if there is a history of prior malignancy | 1 |
| 39 | 39 | and | 1 | note if there is a history of prior malignancy they must not be receiving other specific treatment for their cancer | 1 |
| 40 | 44 | patients who have a history of another primary malignancy from which the patient has been disease free for < 1 year with the exceptions of non melanoma skin cancer and carcinoma in situ of the cervix uteri or | 1 | or prostatic intraepithelial neoplasm note if there is a history or prior malignancy patient must not be receiving other specific treatment other than hormonal therapy for their cancer | 1 |
| 41 | 47 | patients must not have previous or concurrent malignancy exceptions are made for patients who meet any of the following conditions r n non melanoma skin cancer in situ cervical cancer or | 1 | penis | 1 |
| 42 | 54 | other malignancy requiring active therapy r n exceptions non melanoma skin cancer ductal | 1 | oral cavity cervix | 1 |
| 43 | 55 | other active malignancy = < 2 years prior to registration exceptions non melanotic skin cancer or carcinoma in situ of the cervix note if there is a history of prior malignancy they must not be receiving other specific treatment for their cancer note adjuvant anti estrogen / hormonal therapy for | 1 | localized prostate cancer carcinoma in situ of the oral cavity | 1 |
| 44 | 56 | other active malignancy than lymphoma r n note if there is a history of prior malignancy they must not be receiving other specific treatment for their cancer that comcLd interfere with this protocol therapy patients on hormonal therapy for treated | 1 | or cervix are all permissible are permitted even if diagnosed and treated < 3 years ago | 1 |
| 45 | 57 | active other malignancy excepting non melanotic skin cancer or carcinoma in situ e . g . of cervix | 1 | oral cavity or cervix is all permissible | 1 |
| 46 | 58 | other active malignancy = < 6 months prior to registration r n exceptions non melanotic skin cancer or carcinoma in situ of the cervix or or prostate cancer confined to prostate gland or coexistent differentiated thyroid cancer r n note if there is a history of prior malignancy they must not be receiving other treatment for their cancer ongoing adjuvant hormonal treatment for | 1 | oral cavity or cervix are permissible | 1 |
| 47 | 59 | other active malignancy = < 3 years prior to registration exceptions non melanotic skin cancer or carcinoma in situ of the cervix uterus or | 1 | malignancies with a similar outcome to those mentioned above | 1 |
| 48 | 60 | other active malignancy = < 5 years prior to registration exceptions non melanotic skin cancer or carcinoma in situ of the cervix or | 1 | cancer within 5 years prior to treatment initiation except for appropriately treated carcinoma in situ of the cervix non melanoma skin carcinoma or stage i uterine cancer | 1 |
| 49 | 61 | prior invasive malignancy except non melanomatous skin cancer and t1 renal cell carcinoma unless disease free for a minimum of 2 years note that carcinoma in situ of the | 1 | NA | |
| 50 | 62 | no prior or current invasive malignancy except non melanomatous skin cancer localized bladder and prostate cancer unless disease free for a minimum of 2 years for example carcinoma in situ of the | 1 | NA | |
| 51 | 63 | prior invasive malignancy except non melanomatous skin cancer low or intermediate risk prostate cancer or in situ carcinoma of | 1 | NA | |
| 52 | 65 | prior invasive malignancy except node negative non melanomatous skin cancer unless disease free for a minimum of 1095 days 3 years for example carcinoma in situ of the | 1 | NA | |
| 53 | 68 | prior invasive malignancy except non melanomatous skin cancer carcinoma in situ of the male | 1 | NA | |
| 54 | 69 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 3 years carcinoma in situ of the | 1 | NA | |
| 55 | 70 | prior invasive malignancy unless disease free for a minimum of 3 years however skin cancer and in situ carcinomas of the | 1 | NA | |
| 56 | 73 | prior invasive malignancy except non melanoma skin cancer or non life limiting invasive malignancy that may not require treatment such as low risk prostate cancer unless disease free for a minimum of 3 years for example carcinoma in situ of | 1 | NA | |
| 57 | 83 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 2 years e . g . carcinoma in situ of the | 1 | NA | |
| 58 | 85 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 3 years noninvasive cancers for example carcinoma in situ of the | 1 | NA | |
| 59 | 86 | prior or current invasive malignancy except non melanomatous skin cancer localized bladder and prostate cancer unless disease free for a minimum of 2 years for example carcinoma in situ of the | 1 | NA | |
| 60 | 88 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 3 years e . g . carcinoma in situ of the | 1 | NA | |
| 61 | 89 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 1 year for example carcinoma in situ of the | 1 | NA | |
| 62 | 91 | patients with prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 3 years e . g . carcinoma in situ of the | 1 | NA | |
| 63 | 92 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 3 years note carcinoma in situ of the | 1 | NA | |
| 64 | 93 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 730 days 2 years for example carcinoma in situ of the | 1 | NA | |
| 65 | 95 | prior invasive malignancy except non melanomatous skin cancer unless disease free for a minimum of 3 years . for example carcinoma in situ of the | 1 | NA | |
| 66 | 96 | history of invasive cancer in the last 3 years except for appropriately treated low risk prostate cancer treated non melanoma / melanoma skin cancer appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of | 1 | NA | |
| 67 | 97 | appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of | 1 | NA | |
| 68 | 98 | or other non | 1 | NA | |
| 69 | 99 | malignancies other than | 1 | NA |